14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $23.53 $28.69 Friday, 3rd May 2024 INSM stock ended at $25.55. This is 0.429% less than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 4.06% from a day low at $25.40 to a day high of $26.43.
90 days $23.53 $29.91
52 weeks $18.09 $32.00

Historical Insmed prices

Date Open High Low Close Volume
Sep 28, 2023 $25.90 $26.00 $25.11 $25.76 814 823
Sep 27, 2023 $25.76 $26.39 $25.54 $25.90 1 171 973
Sep 26, 2023 $25.94 $26.75 $25.76 $25.77 1 800 841
Sep 25, 2023 $25.96 $26.28 $25.46 $25.78 1 089 754
Sep 22, 2023 $26.49 $26.52 $25.75 $26.17 806 657
Sep 21, 2023 $25.67 $26.42 $25.42 $26.34 993 630
Sep 20, 2023 $26.39 $26.44 $25.43 $25.52 877 306
Sep 19, 2023 $26.53 $26.61 $25.97 $26.31 1 122 793
Sep 18, 2023 $26.62 $26.79 $26.04 $26.55 952 504
Sep 15, 2023 $26.64 $26.79 $26.16 $26.61 2 511 943
Sep 14, 2023 $26.42 $26.68 $26.18 $26.67 1 266 499
Sep 13, 2023 $26.99 $26.99 $26.12 $26.30 1 828 444
Sep 12, 2023 $26.44 $27.59 $26.32 $26.93 1 227 265
Sep 11, 2023 $26.26 $26.56 $26.02 $26.50 1 144 791
Sep 08, 2023 $26.73 $26.73 $25.95 $26.26 1 075 898
Sep 07, 2023 $27.08 $27.15 $26.36 $26.59 1 642 771
Sep 06, 2023 $26.77 $27.05 $25.98 $26.43 2 562 868
Sep 05, 2023 $24.05 $27.15 $24.00 $26.37 9 321 451
Sep 01, 2023 $22.04 $22.65 $22.03 $22.64 822 381
Aug 31, 2023 $22.13 $22.48 $21.84 $21.89 1 052 751
Aug 30, 2023 $21.66 $22.30 $21.65 $22.08 1 378 336
Aug 29, 2023 $21.53 $21.81 $21.21 $21.61 1 324 826
Aug 28, 2023 $21.87 $22.04 $21.49 $21.62 718 567
Aug 25, 2023 $22.02 $22.15 $21.53 $21.84 622 727
Aug 24, 2023 $22.12 $22.43 $21.86 $21.93 801 608
Click to get the best stock tips daily for free!

About Insmed

Insmed Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutr... INSM Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT